Head to Head Review: BioLife Solutions (BLFS) and The Competition
BioLife Solutions (NASDAQ: BLFS) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare BioLife Solutions to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, profitability and earnings.
Institutional & Insider Ownership
2.6% of BioLife Solutions shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 37.7% of BioLife Solutions shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for BioLife Solutions and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioLife Solutions Competitors||827||3702||6739||182||2.55|
BioLife Solutions currently has a consensus price target of $6.00, suggesting a potential downside of 6.69%. As a group, “Pharmaceuticals” companies have a potential upside of 23.38%. Given BioLife Solutions’ rivals higher probable upside, analysts clearly believe BioLife Solutions has less favorable growth aspects than its rivals.
Risk and Volatility
BioLife Solutions has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500. Comparatively, BioLife Solutions’ rivals have a beta of 0.90, meaning that their average share price is 10% less volatile than the S&P 500.
Earnings & Valuation
This table compares BioLife Solutions and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|BioLife Solutions||$9.31 million||-$2.21 million||-13.68|
|BioLife Solutions Competitors||$8.20 billion||$2.68 billion||-1.31|
BioLife Solutions’ rivals have higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares BioLife Solutions and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioLife Solutions Competitors||-2,845.52%||-66.83%||-8.68%|
BioLife Solutions rivals beat BioLife Solutions on 7 of the 12 factors compared.
BioLife Solutions Company Profile
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.